The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Aberrant JAK2 tyrosine kinase signaling drives the development of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. However, JAK2 kinase inhibitors have failed to significantly reduce allele burden...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Adv
Hoofdauteurs: Mazzacurati, Lucia, Collins, Robert J., Pandey, Garima, Lambert-Showers, Que T., Amin, Narmin E., Zhang, Ling, Stubbs, Matthew C., Epling-Burnette, Pearlie K., Koblish, Holly K., Reuther, Gary W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2019
Onderwerpen:
Myeloid Neoplasia
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880903/
https://ncbi.nlm.nih.gov/pubmed/31725895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000260
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items